ロード中...

Targeting Protein Prenylation in Progeria

A clinical trial of a protein farnesyltransferase inhibitor (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS) was recently completed. Here, we discuss the mutation that causes HGPS, the rationale for inhibiting protein farnesyltransferase, the potential limitations of thi...

詳細記述

保存先:
書誌詳細
主要な著者: Young, Stephen G., Yang, Shao H., Davies, Brandon S. J., Jung, Hea-Jin, Fong, Loren G.
フォーマット: Artigo
言語:Inglês
出版事項: 2013
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3725554/
https://ncbi.nlm.nih.gov/pubmed/23390246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3005229
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!